Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hinova PharmaceuticalsSHSE:688302 +2.44%31 PB Ratio is 3.14 as of Jul. 31, 2026, which is 8% below its 10-year median of 3.43. GuruFocus rates SHSE:688302 with a GF Score™ of 31/100. The stock has 2 warning signs investors should review. Among 1,228 Biotechnology companies, Hinova Pharmaceuticals ranks worse than 55.86% on this metric.
Hinova Pharmaceuticals Inc stock PB Ratio (=3.28) is close to 1-year low of 3.17.
The historical rank and industry rank for Hinova Pharmaceuticals's PB Ratio or its related term are showing as below:
SHSE:688302'
s PB Ratio Range Over the Past 10 Years
Min: 1.66 Med: 3.43 Max: 5.75
Current: 3.14
During the past 8 years, Hinova Pharmaceuticals's highest PB Ratio was 5.75. The lowest was 1.66. And the median was 3.43.
SHSE:688302's PB Ratio is ranked worse than 55.86% of 1228
companies
in the Biotechnology industry
Industry Median: 2.705
vs SHSE:688302: 3.14
During the past 12 months, Hinova Pharmaceuticals's average Book Value Per Share Growth Rate was -11.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -12.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 0.10% per year.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Hinova Pharmaceuticals was 204.90% per year. The lowest was -12.50% per year. And the median was 8.05% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688302 vs VRTX, REGN, RVMD: PB Ratio Comparison
For the Biotechnology subindustry, Hinova Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hinova Pharmaceuticals PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hinova Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Hinova Pharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Hinova Pharmaceuticals (SHSE:688302) has a PB Ratio of 3.14 as of Jul. 31, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Hinova Pharmaceuticals and its competitors. This is near median its historical median of 3.43. Over the past decade, Hinova Pharmaceuticals' PB Ratio has ranged from 1.66 to 5.75. According to the industry distribution chart, Hinova Pharmaceuticals ranks #686 out of 1228 companies in the Biotechnology industry, placing it in the top 55.9%.
Is Hinova Pharmaceuticals' PB Ratio too high?
Hinova Pharmaceuticals' current PB Ratio of 3.14 is near median its 10-year median of 3.43. Over the past 10 years, this metric has ranged from a low of 1.66 to a high of 5.75. The Biotechnology industry median PB Ratio is 2.71. Hinova Pharmaceuticals' value of 3.14 is 16.1% above this industry median. Based on the distribution chart, Hinova Pharmaceuticals ranks #686 out of 1228 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Hinova Pharmaceuticals has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Hinova Pharmaceuticals' PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Hinova Pharmaceuticals ranks #686 out of 1228 companies for PB Ratio. This places Hinova Pharmaceuticals in the lower half of its industry. The industry median PB Ratio is 2.71. Hinova Pharmaceuticals' value of 3.14 is 16.1% above this benchmark. Historically, Hinova Pharmaceuticals' own PB Ratio has ranged from 1.66 to 5.75 over the past decade. While the company's 10-year median is 3.43 vs. the industry median of 2.71, Hinova Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.71, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hinova Pharmaceuticals's current PB Ratio of 3.14 is 16.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Hinova Pharmaceuticals and its competitors. For the Biotechnology industry, the median PB Ratio is 2.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hinova Pharmaceuticals's current PB Ratio is 3.14, which is near median its own 10-year median of 3.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hinova Pharmaceuticals stock overvalued right now?
Hinova Pharmaceuticals (SHSE:688302) has a current PB Ratio of 3.14. The current PB Ratio is 3.14, which is near median its 10-year median of 3.43 and 16.1% above the Biotechnology industry median of 2.71. Hinova Pharmaceuticals' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Hinova Pharmaceuticals (SHSE:688302), the current PB Ratio is 3.14 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Hinova Pharmaceuticals Inc is an international drug company based on technology platforms such as deuterium and PROTAC, aiming to develop Best-in-class and First-in-class drugs with major clinical needs. The company focuses on the research and development of drugs in therapeutic areas such as oncology and metabolic diseases, focusing on providing safe, effective and affordable drugs for patients, and is committed to the development and production of drugs with global rights and interests.
31GF Score
Get the complete analysis for SHSE:688302
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688302 has been successfully added to your 
